Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (11769)	2/17/2013 6:37:57 AM
From: NTTG	1 Recommendation Read Replies (1) \| Respond to of 13111

LOL..OK, no point try to to argue with that logic, but you might want to read through the study design for the Moffitt trial, pay particular attention to the timing of the primary lesion treatment and subsequent initiation of lung mets. Might also want to read the companies position of global broad based vaccine effects, and a bit on basic immunology. The company claim is that you don't have to "try" to treat the bystander, it is the 'immune mediated' bennie that results from PV-10 Tx..they want investors to believe that patients achieve two effects with PV-10; primary Tx and bystander effect. You don't have to jump to any conclusion from the care report other that the obvious..the patient was not protected from subsequent metastatic disease by PV-10, the companies global argument did not stand the test of clinical experience. Would argue the same is true for the PII bystander effect in that there is no control group to compare 'natural disease' to the events that occur in PV-10 treated groups, but I know you have already come to a conclusion on that too. I guess if you wanted to claim a silver lining here you would draw attention to the fact that only 1 of 2 cases developed pulmonary mets; so I guess you would conclude a 50% success rate in CR prevention since the other patient did not develop them...in the time frame reported. That would make this case report more successful that the bystander CR reported for PII, but not quite as good as the 3/5 Moffitt data. Or you could just ignore the obvious fact that patients treated with PV-10 do not generate robust immune responses, which you already saw in the poor bystander response rates in the PII trial BTW, this company has never been timid about sharing what they know, and think they know, with investors. Good luck with your investment...amazing